Relmada Therapeutics Inc. (RLMD) — Former ADSTILADRIN® global clinical development leader brings extensive uro-oncology expertise as Relmada prepares to initiate the Phase 3 SPECTRUM program for NDV-01CORAL GABLES, Fla., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Jørn Skibsted Jakobsen, MD, PhD, as Chief Development
Source: GlobeNewswire — read the full announcement there.
See our Relmada Therapeutics company profile for background, links, and more Relmada Therapeutics news.